Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits

Human Gene Therapy

Volumn 7, Issue 8, 1996, Pages 943-957

  Kozarsky, Karen F ^a,b   Bonen, Denise K ^c   Giannoni, Federico ^c   Funahashi, Toru ^c   Wilson, James M ^a,b   Davidson, Nicholas O ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVE SITE; FAMILIAL HYPERCHOLESTEROLEMIA; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; LIVER; NONHUMAN; RABBIT; RNA EDITING; TRANSGENE;

EID: 0029936990     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.8-943     Document Type: Article

References (49)

1. ANANT, S., MACGINNITIE, A., and DAVIDSON, N. (1995). apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol. Chem. 270, 14762-14767.
2. BOWLER, A., REDGRAVE, T., and MAMO, J. (1991). Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Biochem. J. 276, 381-386.
3. BROWN, M., HERZ, J., KOWAL, R., and GOLDSTEIN, J. (1991) The low-density lipoprotein receptor-related protein: double agent or decoy? Curr. Opin. Lipid. 2, 65-72.
4. CHAN, L. (1995). Apolipoprotein B messenger RNA editing: An update. Biochimie 77, 75-78.
5. CHEN, S., HABIB, G., YANG, C., GU, Z., LEE, B., WENT, S., SILBERMAN, S., CAI, S., DESLYPERE, J., ROSSENEU, M., GOTTO, A., LI, W., and CHAN, L. (1987). Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 238, 363-366.
6. CHOWDHURY, J., GROSSMAN, M., GUPTA, S., CHOWDHURY, N., BAKER, J., and WILSON, J. (1991). Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR deficient rabbits. Science 254, 1802-1805.
7. DAMMERMAN, M., and BRESLOW, J. (1995). Genetic basis of lipoprotein disorders. Circulation 91, 505-512.
8. DAVIDSON, N., ANANT, S., and MACGINNITIE, A. (1995). Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr. Opin. Lipid. 6, 70-74.
9. DEMACKER, P., VAN HEIJST, P., and STALENHOEF, A. (1992). A study of the chylomicron metabolism in WHHL rabbits after fat loading. Biochem. J. 285, 641-646.
10. FUNAHASHI, T., GIANNONI, F., DEPAOLI, A., SKAROSI, S., and DAVIDSON, N. (1995). Tissue-specific, developmental and nutritional regulation of REPR gene expression. J. Lipid Res. 36, 414-428.
11. GARCIA, Z., POKSAY, K., BOSTROM, K., JOHNSON, D., BALESTRA, M., SHECHTER, I., and INNERARITY, T. (1992). Characterization of apolipoprotein B mRNA editing from rabbit intestine. Arterioscl. Thromb. 12, 172-179.
12. GAW, A., PACKARD, C., LINDSAY, G., GRIFFIN, B., CASLAKE, M., LORIMER, A., and SHEPHERD, J. (1995). Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res. 36, 158-171.
13. GIANNONI, F., BONEN, D., FUNAHASHI, T., HADJIAGAPIOU, C., BURANT, C., and DAVIDSON, N. (1994). Complementation of apolipoprotein B mRNA editing by human liver accompanied by secretion of apolipoprotein B48. J. Biol. Chem. 269, 5932-5936.
14. HADJIAGAPIOU, C., GIANNONI, F., FUNAHASHI, T., SKAROSI, S., and DAVIDSON, N. (1994). Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein. Nucleic Acids Res. 22, 1874-1879.
15. HAMMOND-WERNETTE, M., GARCIA, Z., ARNOLD, K., and INNERARITY, T. (1989). β-very low density lipoprotein uptake in cultured fibroblasts and smooth muscle cells from Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 9, 501-510.
16. HARDMAN, D., PULLINGER, C., HAMILTON, R., KANE, J., and MALLOY, M. (1991). Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia. J. Clin. Invest. 88, 1722-1729.
17. HAVEL, R., KITA, T., KOTITE, L., KANE, J., HAMILTON, R., GOLDSTEIN, J., and BROWN, M. (1982). Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. Arteriosclerosis 2, 467-474.
18. HERZ, J., and WILLNOW, T. (1995). Lipoprotein and receptor interactions in vivo. Curr. Opin. Lipid. 6, 97-103.
19. HERZ, J., QIU, S.-Q., OESTERLE, A., DESILVA, H., SHAFI, S., and HAVEL, R. (1995). Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 92, 4611-4615.
20. HORNICK, C., KITA, T., HAMILTON, R., KANE, J., and HAVEL, R. (1983). Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA 80, 6069-6100.
21. HUSSAIN, M., INNERARITY, T., BRECHT, W., and MAHLEY, R. (1995a). Chylomicron metabolism in normal, cholesterol-fed, and Watanabe Heritable hyperlipidemic rabbits. J. Biol. Chem. 270, 8578-8587.
22. HUSSAIN, M., ZHAO, Y., KANCHA, R., BLACKHART, B., and YAO, Z. (1995b). Characterization of recombinant human apoB-48-containing lipoproteins in rat hepatoma McA-RH7777 cells transfected with apoB-48 cDNA. Arterioscl. Thromb. Vasc. Biol. 15, 485-494.
23. ISHIBASHI, S., BROWN, M., GOLDSTEIN, J., GERARD, R., HAMMER, R., and HERZ, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893.
24. ISHIBASHI, S., HERZ, J., MAEDA, N., GOLDSTEIN, J., and BROWN, M. (1994). The two-receptor model of lipoprotein clearance: Tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA 91, 4431-4435.
25. JOHNSON, D., POKSAY, K., and INNERARITY, T. (1993). The mechanism for apo B mRNA editing is deamination. Biochem. Biophys. Res. Commun. 195, 1204-1210.
26. KITA, T., GOLDSTEIN, J., BROWN, M., WATANABE, Y., HORNICK, C., and HAVEL, R. (1982). Hepatic uptake of chylomicron remnants in WHHL rabbits: A mechanism genetically distinct from the low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 79, 3623-3627.
27. KOZARSKY, K., GROSSMAN, M., and WILSON, J. (1993). Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somat. Cell Mol. Genet. 19, 449-458.
28. KOZARSKY, K., MCKINLEY, D., AUSTIN, L., RAPER, S., STRATFORD-PERRICAUDET, L., and WILSON, J. (1994). In vivo correction of LDL receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. 269, 13695-13702.
29. LAU, P., ZHU, H.-J., BALDINI, A., CHARNSANGAVEG, C., and CHAN, L. (1994). Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. Proc. Natl. Acad. Sci. USA 91, 8522-8526.
30. LENICH, C., BRECHER, P., MAKRIDES, S., CHOBANIAN, A., and ZANNIS, V. (1988). Apolipoprotein gene expression in the rabbit: Abundance, size and distribution of apolipoprotein mRNA species in different tissues. J. Lipid Res. 29, 755-764.
31. LI, J., FANG, B., EISENSMITH, R., LI, X., NASONKIN, I., LIN-LEE, Y., MIMS, M., HUGHES, A., MONTGOMERY, C., ROBERTS, J., PARKER, T., LEVINE, D., and WOO, S. (1995). In vivo gene therapy for hyperlipidemia: Phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J. Clin. Invest. 95, 768-773.
32. LINTON, M., FARESE, R., and YOUNG, S. (1995). Familial hypobetalipoproteinemia. J. Lipid Res. 34, 521-541.
33. MACGINNITIE, A., ANANT, S., and DAVIDSON, N. (1995). Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J. Biol. Chem. 270, 14768-14775.
34. MAHLEY, R., and HUSSAIN, M. (1991). Chylomicron and chylomicron remnant catabolism. Curr. Opin. Lipid. 2, 170-176.
35. MAMO, J., BOWLER, A., ELSEGOOD, C., and REDGRAVE, T. (1991). Defective plasma clearance of chylomicron-like lipid emulsions in Watanabe heritable hyperlipidemic rabbits. Biochim. Biophys. Acta 1081, 241-245.
36. MCLEOD, R., ZHAO, Y., SELBY, S., WESTERLUND, J., and YAO, Z. (1994). Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins. J. Biol. Chem. 269, 2852-2862.
37. NAKAMUTA, M., OKA, K., KRUSHKAL, J., KOBAYASHI, K., YAMAMOTO, M., LI, W., and CHAN, L. (1995). Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (apobec1) gene in mice. J. Biol. Chem. 270, 13042-13056.
38. NAVARATNAM, N., BHATTACHARYA, S., FUJINO, T., PATEL, D., JARMUZ, A., and SCOTT, J. (1995). Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell 81, 187-195.
39. POWELL, L., WALLIS, S., PEASE, R., EDWARDS, Y., KNOTT, T., and SCOTT, J. (1987). A novel form of tissue-specific RNA processing produces apolipoprotein B-48 in intestine. Cell 50, 831-840.
40. SHIMADA, Y., TANZAWA, K., KURODA, M., TSUJITA, Y., ARAI, M., and WATANABE, Y. (1981). Biochemical characterization of skin fibroblasts derived from WHHL-rabbit, a notable animal model for familial hypercholesterolemia. Eur. J. Biochem. 118, 557-564.
41. TANAKA, M., OTANI, H., YOKODE, M., and KITA, T. (1995). Regulation of apolipoprotein B secretion in hepatocytes from Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Atherosclerosis 114, 73-82.
42. TENG, B., BURANT, C., and DAVIDSON, N.O. (1993). Molecular cloning of an apolipoprotein B mRNA editing protein. Science 260, 1816-1819.
43. TENG, B., BLUMENTHAL, S., FORTE, T., NAVARATNAM, N., SCOTT, J., GOTTO, A.J., and CHAN, L. (1994). Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. J. Biol. Chem. 269, 29395-29404.
44. YAMADA, N., SHAMES, D., TAKAHASHI, K., and HAVEL, R. (1988). Metabolism of apolipoprotein B-100 in large very low density lipoproteins of blood plasma. J. Clin. Invest. 82, 2106-2113.
45. YAMAMOTO, T., BISHOP, R., BROWN, M., GOLDSTEIN, J., and RUSSELL, D. (1986). Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science 232, 1230-1237.
46. YAMANAKA, S., POKSAY, K., BALESTRA, M., ZENG, G., and INNERARITY, T. (1994). Cloning and mutagensis of the rabbit apoB mRNA editing protein: a zinc motif is essential for catalytic activity, and non-catalytic auxiliary factor(s) of the editing complex are widely distributed. J. Biol. Chem. 269, 21725-21734.
47. YAMANAKA, S., BALESTRA, M., FERRELL, L., FAN, J., ARNOLD, K., TAYLOR, S., TAYLOR, J., and INNERARITY, T. (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl. Acad. Sci. USA 92, 8483-8487.
48. YOUNG, S. (1990). Recent progress in understanding apolipoprotein B. Circulation 82, 1574-1594.
49. YOUNG, S., BIHAIN, B., FLYNN, L., SANAN, D., AYRAULT-JARRIER, M., and JACOTOT, B. (1994). Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2. Hum. Mol. Genet. 3, 741-744.